{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:37Z","timestamp":1792190497169,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008765","name":"Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de Gastro-Ent\u00e9rologie","doi-asserted-by":"publisher","award":["MAHGE"],"award-info":[{"award-number":["MAHGE"]}],"id":[{"id":"10.13039\/501100008765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00428-024-03922-5","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:02:33Z","timestamp":1725631353000},"page":"901-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prognostic impact of the tumour microenvironment in intrahepatic cholangiocarcinoma: identification of a peritumoural fibro-immune interface"],"prefix":"10.1007","volume":"485","author":[{"given":"Gwladys","family":"Lubuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-058X","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Beaufr\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Pignollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Nicolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Lesurtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Cros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"3922_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","volume":"33","author":"T Patel","year":"2001","unstructured":"Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353\u20131357. https:\/\/doi.org\/10.1053\/jhep.2001.25087","journal-title":"Hepatology"},{"key":"3922_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.suronc.2016.12.009","volume":"26","author":"AA Rahnemai-Azar","year":"2017","unstructured":"Rahnemai-Azar AA, Weisbrod A, Dillhoff M et al (2017) Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surg Oncol 26:125\u2013137. https:\/\/doi.org\/10.1016\/j.suronc.2016.12.009","journal-title":"Surg Oncol"},{"key":"3922_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM (2014) Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. JAMA Surg 149:565\u2013574. https:\/\/doi.org\/10.1001\/jamasurg.2013.5137","journal-title":"JAMA Surg"},{"key":"3922_CR4","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","volume":"72","author":"MA Martin-Serrano","year":"2023","unstructured":"Martin-Serrano MA, Kepecs B, Torres-Martin M et al (2023) Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 72:736\u2013748. https:\/\/doi.org\/10.1136\/gutjnl-2021-326514","journal-title":"Gut"},{"key":"3922_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/cells12060846","volume":"12","author":"F Vita","year":"2023","unstructured":"Vita F, Olaizola I, Amato F et al (2023) Heterogeneity of Cholangiocarcinoma Immune Biology. Cells 12:846. https:\/\/doi.org\/10.3390\/cells12060846","journal-title":"Cells"},{"key":"3922_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","volume":"73","author":"M Zhang","year":"2020","unstructured":"Zhang M, Yang H, Wan L et al (2020) Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol 73:1118\u20131130. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.039","journal-title":"J Hepatol"},{"key":"3922_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","volume":"73","author":"L Fabris","year":"2021","unstructured":"Fabris L, Sato K, Alpini G, Strazzabosco M (2021) The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology 73:75\u201385. https:\/\/doi.org\/10.1002\/hep.31410","journal-title":"Hepatology"},{"key":"3922_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41379-020-00656-y","volume":"34","author":"N Guedj","year":"2021","unstructured":"Guedj N, Blaise L, Cauchy F et al (2021) Prognostic value of desmoplastic stroma in intrahepatic cholangiocarcinoma. Mod Pathol 34:408\u2013416. https:\/\/doi.org\/10.1038\/s41379-020-00656-y","journal-title":"Mod Pathol"},{"key":"3922_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/1535-7163.MCT-11-0340","volume":"11","author":"WN Brennen","year":"2012","unstructured":"Brennen WN, Isaacs JT, Denmeade SR (2012) Rationale Behind Targeting Fibroblast Activation Protein-Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy. Mol Cancer Ther 11:257\u2013266. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0340","journal-title":"Mol Cancer Ther"},{"key":"3922_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3748\/wjg.v18.i8.840","volume":"18","author":"M Shi","year":"2012","unstructured":"Shi M, Yu D-H, Chen Y et al (2012) Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol 18:840\u2013846. https:\/\/doi.org\/10.3748\/wjg.v18.i8.840","journal-title":"World J Gastroenterol"},{"key":"3922_CR11","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"X Yang","year":"2016","unstructured":"Yang X, Lin Y, Shi Y et al (2016) FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res 76:4124\u20134135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2973","journal-title":"Cancer Res"},{"key":"3922_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","volume":"21","author":"Y Lin","year":"2019","unstructured":"Lin Y, Li B, Yang X et al (2019) Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia 21:1133\u20131142. https:\/\/doi.org\/10.1016\/j.neo.2019.10.005","journal-title":"Neoplasia"},{"key":"3922_CR13","doi-asserted-by":"publisher","unstructured":"Harms PW, Frankel TL, Moutafi M et al (2023) Multiplex immunohistochemistry and immunofluorescence: a practical update for pathologists. Modern Pathology 36:100197. https:\/\/doi.org\/10.1016\/j.modpat.2023.100197","DOI":"10.1016\/j.modpat.2023.100197"},{"key":"3922_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1369\/jhc.2009.953240","volume":"57","author":"D Pirici","year":"2009","unstructured":"Pirici D, Mogoanta L, Kumar-Singh S et al (2009) Antibody Elution Method for Multiple Immunohistochemistry on Primary Antibodies Raised in the Same Species and of the Same Subtype. J Histochem Cytochem 57:567\u2013575. https:\/\/doi.org\/10.1369\/jhc.2009.953240","journal-title":"J Histochem Cytochem"},{"key":"3922_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/his.12446","volume":"65","author":"M Van Den Brand","year":"2014","unstructured":"Van Den Brand M, Hoevenaars BM, Sigmans JHM et al (2014) Sequential immunohistochemistry: a promising new tool for the pathology laboratory. Histopathology 65:651\u2013657. https:\/\/doi.org\/10.1111\/his.12446","journal-title":"Histopathology"},{"key":"3922_CR16","doi-asserted-by":"publisher","unstructured":"Schumacher TN, Thommen DS\u00a0(2022) Tertiary lymphoid structures in cancer. Science (New York, NY) 375. https:\/\/doi.org\/10.1126\/science.abf9419","DOI":"10.1126\/science.abf9419"},{"key":"3922_CR17","doi-asserted-by":"publisher","unstructured":"Galon J, Mlecnik B, Bindea G et al (2014) Towards the introduction of the \u201cImmunoscore\u201d in the classification of malignant tumours. J Pathol 232. https:\/\/doi.org\/10.1002\/path.4287","DOI":"10.1002\/path.4287"},{"key":"3922_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MPA.0b013e31816618ce","volume":"37","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Alpaugh RK, Palazzo I et al (2008) Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37:154\u2013158. https:\/\/doi.org\/10.1097\/MPA.0b013e31816618ce","journal-title":"Pancreas"},{"key":"3922_CR19","doi-asserted-by":"publisher","first-page":"969731","DOI":"10.3389\/fonc.2022.969731","volume":"12","author":"C Cheng","year":"2022","unstructured":"Cheng C, Yang P, Sun Y et al (2022) Fibroblast activation protein-based theranostics in pancreatic cancer. Front Oncol 12:969731. https:\/\/doi.org\/10.3389\/fonc.2022.969731","journal-title":"Front Oncol"},{"key":"3922_CR20","doi-asserted-by":"publisher","first-page":"e92232","DOI":"10.1172\/jci.insight.92232","volume":"2","author":"A Lo","year":"2017","unstructured":"Lo A, Li C-P, Buza EL et al (2017) Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight 2:e92232. https:\/\/doi.org\/10.1172\/jci.insight.92232","journal-title":"JCI Insight"},{"key":"3922_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.5604\/01.3001.0012.0929","volume":"17","author":"SO Antwi","year":"2018","unstructured":"Antwi SO, Mousa OY, Patel T (2018) Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995\u20132014. Ann Hepatol 17:604\u2013614. https:\/\/doi.org\/10.5604\/01.3001.0012.0929","journal-title":"Ann Hepatol"},{"key":"3922_CR22","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.jhepr.2023.100762","volume":"5","author":"C Zhu","year":"2023","unstructured":"Zhu C, Ma J, Zhu K et al (2023) Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma. JHEP Rep 5:100762. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100762","journal-title":"JHEP Rep"},{"key":"3922_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.02.026","volume":"60","author":"HH Workel","year":"2016","unstructured":"Workel HH, Komdeur FL, Wouters MCA et al (2016) CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur J Cancer 60:1\u201311. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.026","journal-title":"Eur J Cancer"},{"key":"3922_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/ijo.2023.5585","volume":"63","author":"S Yang","year":"2023","unstructured":"Yang S, Zou R, Dai Y et al (2023) Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review). Int J Oncol 63:137. https:\/\/doi.org\/10.3892\/ijo.2023.5585","journal-title":"Int J Oncol"},{"key":"3922_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jhep.2023.05.010","volume":"79","author":"JL Tomlinson","year":"2023","unstructured":"Tomlinson JL, Valle JW, Ilyas SI (2023) Immunobiology of cholangiocarcinoma. J Hepatol 79:867\u2013875. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.010","journal-title":"J Hepatol"},{"key":"3922_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K et al (2023) Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 78:770\u2013782. https:\/\/doi.org\/10.1016\/j.jhep.2023.01.011","journal-title":"J Hepatol"},{"key":"3922_CR27","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM (2020) The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev 39:783\u2013803. https:\/\/doi.org\/10.1007\/s10555-020-09909-3","journal-title":"Cancer Metastasis Rev"},{"key":"3922_CR28","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","volume":"330","author":"M Kraman","year":"2010","unstructured":"Kraman M, Bambrough PJ, Arnold JN et al (2010) Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein\u2013\u03b1. Science 330:827\u2013830. https:\/\/doi.org\/10.1126\/science.1195300","journal-title":"Science"},{"key":"3922_CR29","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S et al (2022) Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence 1:EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evidence"},{"key":"3922_CR30","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/thno.69475","volume":"12","author":"L Zhao","year":"2022","unstructured":"Zhao L, Chen J, Pang Y et al (2022) Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. Theranostics 12:1557\u20131569. https:\/\/doi.org\/10.7150\/thno.69475","journal-title":"Theranostics"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03922-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T19:04:21Z","timestamp":1731611061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03922-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3922"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03922-5","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"18 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent was obtained from all patients as required by French legislation. This study was approved by the local ethics committee (CEERB PARIS NORD IRB00006477, protocol no. CER-2022\u2013168).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The RNA-seq data have been deposited in Gene Expression Omnibus (GEO) (accession no. GSE244807).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transcript Profiling"}}]}}